Status:
UNKNOWN
Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Conditions:
Thyroid Carcinoma
Metastatic Sites Lung Bone Nodal
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The main purpose of the study is to establish a relationship between the administered activity of the radioiodine and absorbed dose in the tumor sites.
Detailed Description
Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid cancer to correlate the administered activity to absorbed dose. Patients will receive the standard therapy ...
Eligibility Criteria
Inclusion
- age above 18
- histological confirmation of the differentiated thyroid carcinoma available
- WHO performance score 0-2
- metastatic sites lung and/or bone and/or nodal (radiologically measurable disease \> 1 cm)
- life expectancy \> 6 months
- patient has undergone total/near total thyroidectomy
- no past history of sensitivity/reaction to 1311
Exclusion
- non iodine concentrating tumours
- received chemotherapy or radiotherapy in 6 weeks
- pregnant or breast feeding patients
- iodine contrast injection in last 3 months
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00749697
Start Date
May 1 2008
End Date
July 1 2010
Last Update
September 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Marsden NHS Foundation Trust
London, Sutton, United Kingdom, SM2 5PT